BR112014012849A2 - derivados de espirotienopirano-piperidina como antagonistas do receptor de orl-1 para seu uso no tratamento de dependência e abuso de álcool - Google Patents

derivados de espirotienopirano-piperidina como antagonistas do receptor de orl-1 para seu uso no tratamento de dependência e abuso de álcool

Info

Publication number
BR112014012849A2
BR112014012849A2 BR112014012849A BR112014012849A BR112014012849A2 BR 112014012849 A2 BR112014012849 A2 BR 112014012849A2 BR 112014012849 A BR112014012849 A BR 112014012849A BR 112014012849 A BR112014012849 A BR 112014012849A BR 112014012849 A2 BR112014012849 A2 BR 112014012849A2
Authority
BR
Brazil
Prior art keywords
orl
treatment
receptor antagonists
spirothienopyran
abuse
Prior art date
Application number
BR112014012849A
Other languages
English (en)
Inventor
Rorick Kehn Linda
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112014012849A2 publication Critical patent/BR112014012849A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

resumo patente de invenção: "derivados de espirotienopirano-piperidina como antagonistas do receptor de orl-1 para seu uso no tratamento de dependência e abuso de álcool". a presente invenção refere-se ao uso de antagonistas do receptor de orl-1 da fórmula (i): (i) para o tratamento de transtornos causados pelo uso de álcool.
BR112014012849A 2011-12-06 2012-11-29 derivados de espirotienopirano-piperidina como antagonistas do receptor de orl-1 para seu uso no tratamento de dependência e abuso de álcool BR112014012849A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161567242P 2011-12-06 2011-12-06
PCT/US2012/066918 WO2013085781A1 (en) 2011-12-06 2012-11-29 Spirothienopyran- piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse

Publications (1)

Publication Number Publication Date
BR112014012849A2 true BR112014012849A2 (pt) 2017-06-13

Family

ID=47279166

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012849A BR112014012849A2 (pt) 2011-12-06 2012-11-29 derivados de espirotienopirano-piperidina como antagonistas do receptor de orl-1 para seu uso no tratamento de dependência e abuso de álcool

Country Status (28)

Country Link
US (1) US9371335B2 (pt)
EP (1) EP2787995B1 (pt)
JP (1) JP6002778B2 (pt)
KR (1) KR101638265B1 (pt)
CN (1) CN103987387B (pt)
AP (1) AP3880A (pt)
AU (1) AU2012348140B2 (pt)
BR (1) BR112014012849A2 (pt)
CA (1) CA2853500C (pt)
DK (1) DK2787995T3 (pt)
EA (1) EA022874B1 (pt)
ES (1) ES2600911T3 (pt)
HK (1) HK1196943A1 (pt)
HR (1) HRP20161351T1 (pt)
HU (1) HUE029439T2 (pt)
IL (1) IL232654A (pt)
LT (1) LT2787995T (pt)
MX (1) MX352997B (pt)
MY (1) MY172809A (pt)
PL (1) PL2787995T3 (pt)
PT (1) PT2787995T (pt)
RS (1) RS55182B1 (pt)
SG (1) SG11201402745UA (pt)
SI (1) SI2787995T1 (pt)
TW (1) TWI582096B (pt)
UA (1) UA113859C2 (pt)
WO (1) WO2013085781A1 (pt)
ZA (1) ZA201403927B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
PT3589638T (pt) 2017-03-02 2021-05-27 Lilly Co Eli Compostos úteis para inibição do ror-gama-t
EP3589637B1 (en) * 2017-03-02 2021-04-14 Eli Lilly and Company Compounds useful for inhibiting ror-gamma-t
CN109400618B (zh) * 2018-11-09 2021-08-10 中国药科大学 一种色满衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140032A (en) * 1990-10-01 1992-08-18 Radecki Thomas E Drug therapy for alcohol abusers
EP1873150A1 (en) * 2006-06-30 2008-01-02 Nikem Research S.R.L. Fluorinated indoleamides useful as ligands of the ORL-1 receptor
US8207201B2 (en) * 2006-10-16 2012-06-26 Mitsubishi Tanabe Pharma Corporation Agent for prophylaxis or treatment of alcohol dependence or drug dependence
UA107943C2 (en) * 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
PT2501704E (pt) * 2009-11-16 2013-12-05 Lilly Co Eli Compostos de espiropiperidina como antagonistas do receptor orl-1

Also Published As

Publication number Publication date
RS55182B1 (sr) 2017-01-31
HK1196943A1 (zh) 2014-12-24
AU2012348140B2 (en) 2015-09-17
CA2853500A1 (en) 2013-06-13
PT2787995T (pt) 2016-09-21
HRP20161351T1 (hr) 2016-12-02
CN103987387A (zh) 2014-08-13
KR101638265B1 (ko) 2016-07-08
EA201490938A1 (ru) 2014-09-30
EP2787995A1 (en) 2014-10-15
KR20140088894A (ko) 2014-07-11
IL232654A0 (en) 2014-06-30
CA2853500C (en) 2016-10-04
MX2014006824A (es) 2015-02-12
UA113859C2 (xx) 2017-03-27
SI2787995T1 (sl) 2016-10-28
LT2787995T (lt) 2016-11-25
TW201335163A (zh) 2013-09-01
TWI582096B (zh) 2017-05-11
EA022874B1 (ru) 2016-03-31
AP2014007675A0 (en) 2014-06-30
US9371335B2 (en) 2016-06-21
MX352997B (es) 2017-12-15
JP2015502956A (ja) 2015-01-29
JP6002778B2 (ja) 2016-10-05
EP2787995B1 (en) 2016-08-17
MY172809A (en) 2019-12-12
HUE029439T2 (en) 2017-02-28
PL2787995T3 (pl) 2017-02-28
US20140309251A1 (en) 2014-10-16
NZ624201A (en) 2016-06-24
IL232654A (en) 2017-09-28
AU2012348140A1 (en) 2014-05-22
SG11201402745UA (en) 2014-06-27
CN103987387B (zh) 2016-12-28
ES2600911T3 (es) 2017-02-13
WO2013085781A1 (en) 2013-06-13
DK2787995T3 (en) 2016-11-28
AP3880A (en) 2016-10-31
ZA201403927B (en) 2016-01-27

Similar Documents

Publication Publication Date Title
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BR112014030165A2 (pt) inibidores do bromodomínio de benzo [c] isoxazoloazepina e seu uso
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
CO7020872A2 (es) Agentes de arn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
BR112014014184A2 (pt) triazolopiridinas substituídas e seu uso como inibidores de ttk
BR112014002245A2 (pt) derivados de piridin-2(1h)-ona como inibidores de jak
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
BR112015007231A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BR112013028908A2 (pt) anticorpos c-kit e usos dos mesmos
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015016395A2 (pt) pirazóis 3-substituídos e uso como inibidores de dlk
BR112014013108A2 (pt) compostos tricíclicos fundidos como inibidores da quinase raf
CR20140037A (es) Antagonistas trpm8 y su uso en tratamientos
BR112015009649A2 (pt) composto de triazolo
BR112015025354A2 (pt) compostos di-hidropirido-pirimidínicos como inibidores de autotaxina
BR112012011710A2 (pt) composto de espiropiperidina como antagonistas de receptor de orl-1, sua composição farmacêutica e seu uso
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
BR112013000059A2 (pt) derivados de piperidina e seus usos para o tratamento de distúrbios metabólicos
BR112015007647A2 (pt) derivados de quetamina
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
UY31922A (es) Compuestos
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2646 DE 21/09/2021.